Nivolumab v léčbě NSCLC
| Title in English | Nivolumab in the therapy of NSCLC |
|---|---|
| Authors | |
| Year of publication | 2018 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapie |
| MU Faculty or unit | |
| Citation | |
| Keywords | nivolumab; squamous lung cancer; nonsquamous lung cancer; NSCLC |
| Description | Nivolumab is fully human IgG4 antibody that selectively blocks the interaction between PD-1 and PD-L1/PD-L2 and restarts the immune respone against tumor cells. |